Phase II/III Trial of Temozolomide With or Without Veliparib in Glioblastoma Multiforme
This trial is evaluating the efficacy of temozolomide combined with veliparib versus temozolomide alone in glioblastoma patients.
Asset / Drug
Drug and asset intelligence for Temozolomide with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.